Efficacy and safety of COVID-19 vaccination in patients with cirrhosis

Table 1 Main characteristics of enrolled patients by group

	Vaccinated (n = 89)	Unvaccinated (n = 148)	P value
Age, yr	59 [48-68]	57 [47-64]	0.161
Male/Female	50/39	66/82	0.055
Child-Turcotte-Pugh class A	52 (58.4%)	72 (48.6%)	0.092
Child-Turcotte-Pugh classes B and C	37 (41.6%)	76 (51.4%)
Etiology of cirrhosis
Hepatitis B virus	3 (3.4%)	9 (6.1%)	0.275
Hepatitis C virus	16 (18.0%)	29 (15.6%)	0.449
Alcohol	41 (46.0%)	56 (37.8%)	0.094
Metabolic associated liver disease	5 (5.6%)	7 (4.7%)	0.492
Autoimmune hepatitis	1 (1.1%)	9 (6.1%)	0.059
Primary biliary cholangitis	9 (10.1%)	8 (5.4%)	0.136
Primary sclerosing cholangitis	1 (1.1%)	2 (1.4%)	0.684
Wilson disease	1 (1.1%)	1 (0.7%)	0.611
Other	0	6 (4.1%)	0.057
Mixed	12 (13.5%)	21 (14.2%)	0.521
Comorbidity
Diabetes mellitus	18 (20.2%)	21 (14.2%)	0.151
Ischemic heart disease	7 (7.9%)	6 (4.1%)	0.170
Cancer	9 (10.1%)	12 (8.1%)	0.381
Hepatocellular carcinoma	1 (1.1%)	4 (2.7%)	0.379
Asthma	3 (3.4%)	2 (1.4%)	0.274
Chronic obstructive pulmonary disease	5 (5.6%)	2 (1.4%)	0.071